Piper Sandler Increases KORU Medical Systems (NASDAQ:KRMD) Price Target to $3.50

KORU Medical Systems (NASDAQ:KRMD) had its price target raised by Piper Sandler from $3.00 to $3.50 in a report published on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, B. Riley started coverage on shares of KORU Medical Systems in a report on Thursday, July 25th. They issued a “buy” rating and a $4.00 price target on the stock.

KORU Medical Systems Trading Up 3.2 %

KRMD stock traded up $0.10 during trading on Thursday, reaching $3.18. 89,967 shares of the stock traded hands, compared to its average volume of 114,646. The business’s 50 day moving average price is $2.65 and its 200-day moving average price is $2.47. The firm has a market capitalization of $145.80 million, a PE ratio of -12.48 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.77 and a quick ratio of 3.27. KORU Medical Systems has a 52-week low of $1.98 and a 52-week high of $3.40.

Institutional Trading of KORU Medical Systems

Hedge funds have recently made changes to their positions in the company. Aaron Wealth Advisors LLC acquired a new stake in KORU Medical Systems during the 2nd quarter valued at $28,000. Allspring Global Investments Holdings LLC purchased a new position in KORU Medical Systems in the 2nd quarter valued at about $28,000. Legato Capital Management LLC acquired a new stake in shares of KORU Medical Systems during the second quarter valued at about $35,000. Virtu Financial LLC purchased a new position in shares of KORU Medical Systems during the 1st quarter valued at approximately $63,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in KORU Medical Systems during the 2nd quarter worth $107,000. Hedge funds and other institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.